AstraZeneca plc, founded in 1999 and headquartered in Cambridge, UK, is a global biopharmaceutical company dedicated to the discovery, development, and commercialization of prescription medicines. The company focuses on oncology, cardiovascular, renal, and respiratory therapies, alongside a notable pipeline in rare diseases and vaccine development.
Company overview and issue history are AI generated, and should not be cited or relied on without verification.
AstraZeneca began issuing bonds in 2003, expanding its capital structure to support research and development initiatives. Notable issuances include a €1 billion bond in 2020, which funded the company's COVID-19 vaccine manufacturing efforts. Current yields on AstraZeneca bonds are competitive, falling within the 1.5%-2.5% range, which is favorable compared to industry averages. The company’s bonds also feature a mix of callable and fixed-rate structures, appealing to a range of investors considering both stability and potential for early redemption.